期刊文献+

高血压患者血清脂蛋白(a)浓度与颈动脉粥样硬化斑块的相关性研究 被引量:2

Relationship between the level of lipoprotein(a) and carotid atherosclerotic plaques in patients with high blood pressure
下载PDF
导出
摘要 目的观察在低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)是否达标的高血压患者中血浆脂蛋白(a)[lipoprotein(a),Lp(a)]的浓度,及其与颈动脉粥样硬化斑块形成的相关性。方法入选高血压病史5年以上的高血压患者530例,按照LDL-C达标与否进行分层,再将每层按照有无颈动脉斑块进行分组,分为LDL-C达标有斑块组(A组)、LDL-C达标无斑块组(B组)、LDL-C未达标有斑块组(C组)和LDL-C未达标无斑块组(D组),观察各组Lp(a)的浓度。结果(1)LDL-C达标组患者的Lp(a)浓度低于LDL-C未达标组,其差异有统计学意义(P<0.01);(2)在LDL-C达标组中,A组患者Lp(a)浓度大于B组,但差异无统计学意义(P>0.05);在LDL-C未达标组中,C组患者Lp(a)浓度大于D组,差异具有统计学意义(P<0.01)。结论对于入院时LDL-C已达标的患者,基线Lp(a)浓度与颈动脉粥样硬化斑块发生无明显相关。然而,对于入院时LDL-C未达标的患者,基线Lp(a)浓度升高可能是颈动脉粥样硬化斑块形成的预测因素。 Objective To observe the serum level of lipoprotein( a) in high blood pressure patients with low density lipopro-tein cholesterol (LDL-C) standards and its association with carotid atherosclerotic plaques. Methods Five hundred and thirty patients with history of hypertension for over 5 years were recruited for the study. They were stratified by depending on whether or not they reached the LDL-C standards. Then, by depending on whether there was presence of carotid plaques in each layer, they were divided into 4 groups: Group A with LDL-C standards and plaques, Group B with LDL-C standards but without plaques, Group C without LDL- C standards but with plaques, Group D without LDL-C standards but without plaques. Close observations were made on the levels of Lp (a) in each groups. Results (1 ) The Lp ( a) levels of the groups with LDL-C standards were lower than those of the groups without LDL-C standards. Statistical significance could be noticed when comparisons were made between them(P 〈0.01). (2) In the group with LDL-C standards, the Lp (a) level in the patients of Group A was higher than that in the patients of Group B, but there was no statistical significance when comparisons were made between them(P 〉0. 05) . In the group without LDL-C standards, the Lp ( a) level in the patients of Group C was higher than that in the patients of Group D, with statistical significance( P 〈0. 01) . Conclusion For the patients with LDL- C level reaching the required standards at the admission, baseline level of Lp (a) seemed to have no obvious corre-lation with carotid atherosclerotic plaques. However, for the patients without LDL-C level reaching the required standards at the admis-sion, elevated baseline LDL-C level might be a predicting factor in the formation of carotid atherosclerotic plaques.
出处 《海军医学杂志》 2017年第3期229-231,共3页 Journal of Navy Medicine
基金 海军后勤科研项目(CHJ12L024)
关键词 低密度脂蛋白胆固醇 脂蛋白(a) 颈动脉粥样硬化斑块 Low-density lipoprotein cholesterol Lipoprotei( a) Carotid atherosclerotic plaque
  • 相关文献

参考文献2

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献451

同被引文献32

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部